ArticleAnnals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists2010
Neuroticism but not omega-3 fatty acid levels correlate with early responsiveness to escitalopram.
Article in Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 3 syntheses or guidelines pooled it, 13 citations in OpenAlex.
- Omega-3 fatty acids for depression in adults.The Cochrane database of systematic reviews · 2021Pooled it
- Meta-analysis and meta-regression of omega-3 polyunsaturated fatty acid supplementation for major depressive disorder.Translational psychiatry · 2016Pooled it
- Omega-3 fatty acids for depression in adults.The Cochrane database of systematic reviews · 2015Pooled it
- Interactions between neuroticism and stressful life events predict response to pharmacotherapy for major depression: A CAN-BIND 1 report.Personality and mental health · 2021Article
- Presence of neuroticism and antidepressant remission rates in late-life depression: results from the Neurobiology of Late-Life Depression (NBOLD) study.International psychogeriatrics · 2018Article
- Cognitive enhancers for anxiety disorders.Pharmacology, biochemistry, and behavior · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
backgroundOmega-3 fatty acid (O3FA) levels and dimensional personality measures have been associated with major depression and the course of depressive illness. We sought to study the utility of O3FA levels and dimensional personality measures as predictors of early improvement with escitalopram.
methodsTwenty-four participants were enrolled in an open-label trial of escitalopram 10 mg/d for 4 weeks. Baseline erythrocyte O3 levels and dimensional personality assessments were obtained.
resultsUsing a conservative, intention-to-treat analysis, baseline neuroticism (r = -0.57; P = .007), as measured by the Revised NEO Personality Inventory but not erythrocyte O3 levels, was correlated with improvements on escitalopram. A facet analysis of the neuroticism domain showed the relationship with antidepressant response to be focused on trait anxiety (r = -0.65; P = .002).
conclusionsAnxiety may have important prognostic implications on subsequent response to selective serotonin reuptake inhibitors, such as escitalopram.
Indexed as
Identifiers
20680188PMC3035677W48333503What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.